Education
About Us
Working with TipRanks
Follow Us
Summit Therapeutics (SMMT)
NASDAQ:SMMT
RESEARCH TOOLSreports
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.1Last Year’s EPS
-0.06Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 24, 2025
|% Change Since: -6.46%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Summit Therapeutics, marked by significant collaborations, financial stability, and progress in clinical trials. However, some uncertainties around trial timelines and reliance on partnerships were noted.Company Guidance
During Summit Therapeutics' fourth quarter and year-end 2024 earnings call, the company provided several key metrics and updates regarding their lead investigational asset, Ivonescimab. Notably, they announced a clinical trial collaboration with Pfizer, aiming to evaluate Ivonescimab in combination with multiple Pfizer antibody drug conjugates in unique solid tumor settings, with clinical trials expected to start mid-2025. The company also highlighted the completion of enrollment and Fast Track designation for their global Phase III trial, HARMONi, targeting EGFR mutated advanced non-small cell lung cancer, with top-line data anticipated in mid-2025. Additionally, the HARMONi-3 trial was expanded to include a broader patient population, now addressing a group two to three times larger than initially planned. Financially, Summit ended 2024 with approximately $412 million in cash and zero debt, positioning them well to execute their ongoing and planned clinical trials.Ivonescimab Collaboration with Pfizer
Summit announced a clinical trial collaboration with Pfizer to evaluate Ivonescimab in combination with multiple Pfizer ADCs in solid tumor settings, with trials expected to start mid-2025.
Progress on Global Phase III Trials
Summit completed enrollment in the HARMONi Phase III trial for EGFR mutated non-small cell lung cancer and received Fast Track designation. The HARMONi-3 protocol was expanded to include both squamous and non-squamous histologies, doubling the patient population.
Strong Financial Position
Summit ended 2024 with $412 million in cash and no debt, enabling continued execution of clinical trials.
Ivonescimab Development Milestones
Ivonescimab was featured in 14 publications across 7 tumor types in 2024 and was selected for five oral presentations at major medical conferences.
Global Clinical Trials and Expansions
Summit and Akeso have multiple Phase III trials underway for Ivonescimab, including new indications like pancreatic cancer.
---
SMMT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SMMT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 24, 2025 | $22.12 | $18.84 | -14.83% |
| Oct 30, 2024 | $21.83 | $18.65 | -14.57% |
| Aug 06, 2024 | $10.02 | $9.54 | -4.79% |
| May 01, 2024 | $3.93 | $4.70 | +19.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Summit Therapeutics (SMMT) report earnings?
Summit Therapeutics (SMMT) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Summit Therapeutics (SMMT) earnings time?
Summit Therapeutics (SMMT) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SMMT EPS forecast?
SMMT EPS forecast for the fiscal quarter 2025 (Q1) is -0.1.
---